Dyadic Closes $13 Million Private Placement
02 Décembre 2006 - 12:18AM
Business Wire
Dyadic International, Inc. (AMEX:DIL), a biotechnology company,
announced today that it has closed the previously announced private
placement with institutional investors of 2,787,000 shares of
common stock and warrants to purchase up to 557,400 shares of
common stock for gross proceeds of $13,043,160. The warrants will
become exercisable on the 181st day from issuance, expire three
years thereafter, have an exercise price of $6.33 per share and
will be callable by the Company under certain circumstances. Cowen
and Company, LLC, acted as the exclusive placement agent for the
offering. The securities offered in the private placement have not
been registered under the Securities Act of 1933, as amended (the
�Act�) or any state securities laws, and may not be offered or sold
in the United States absent registration, or an applicable
exemption from registration, under the Act and applicable state
securities laws. For additional information regarding the private
placement, reference is made to Dyadic�s Current Report on Form 8-K
dated November 17, 2006, as filed with the Securities and Exchange
Commission on November 21, 2006. About Dyadic Dyadic International,
Inc. is engaged in the development, manufacture and sale of
biological products using a number of proprietary fungal strains to
produce enzymes and other biomaterials, principally focused on a
system for protein production based on the patented Chrysosporium
lucknowense fungus, known as C1. Dyadic is applying its
technologies to produce enzymes for use in converting various
agricultural products (e.g. corn) and waste products (e.g. switch
grass, wheat straw, sugar cane bagasse, etc.) into fermentable
sugars, which can then be used in the production of traditional and
cellulosic ethanol as well as other products currently derived from
petroleum. Dyadic's C1 technology also is being developed to
facilitate the discovery, development and large-scale production of
human antibodies and other high-value therapeutic proteins. Dyadic
currently sells more than 45 liquid and dry enzyme products to more
than 200 industrial customers in approximately 50 countries for the
textile, pulp & paper and animal feed industries. Cautionary
Statement for Forward-Looking Statements Certain statements
contained in this press release are "forward-looking statements."
These forward-looking statements involve risks and uncertainties
that could cause our actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. For a discussion of these risks and uncertainties,
please see our filings from time to time with the Securities and
Exchange Commission, which are available free of charge on the
SEC's web site at http://www.sec.gov, including our Annual Report
on Form 10-KSB for the year ended December 31, 2005, and our
subsequent filings with the SEC. Except as required by law, we
expressly disclaim any intent or obligation to update any
forward-looking statements. Dyadic International, Inc. (AMEX:DIL),
a biotechnology company, announced today that it has closed the
previously announced private placement with institutional investors
of 2,787,000 shares of common stock and warrants to purchase up to
557,400 shares of common stock for gross proceeds of $13,043,160.
The warrants will become exercisable on the 181st day from
issuance, expire three years thereafter, have an exercise price of
$6.33 per share and will be callable by the Company under certain
circumstances. Cowen and Company, LLC, acted as the exclusive
placement agent for the offering. The securities offered in the
private placement have not been registered under the Securities Act
of 1933, as amended (the "Act") or any state securities laws, and
may not be offered or sold in the United States absent
registration, or an applicable exemption from registration, under
the Act and applicable state securities laws. For additional
information regarding the private placement, reference is made to
Dyadic's Current Report on Form 8-K dated November 17, 2006, as
filed with the Securities and Exchange Commission on November 21,
2006. About Dyadic Dyadic International, Inc. is engaged in the
development, manufacture and sale of biological products using a
number of proprietary fungal strains to produce enzymes and other
biomaterials, principally focused on a system for protein
production based on the patented Chrysosporium lucknowense fungus,
known as C1. Dyadic is applying its technologies to produce enzymes
for use in converting various agricultural products (e.g. corn) and
waste products (e.g. switch grass, wheat straw, sugar cane bagasse,
etc.) into fermentable sugars, which can then be used in the
production of traditional and cellulosic ethanol as well as other
products currently derived from petroleum. Dyadic's C1 technology
also is being developed to facilitate the discovery, development
and large-scale production of human antibodies and other high-value
therapeutic proteins. Dyadic currently sells more than 45 liquid
and dry enzyme products to more than 200 industrial customers in
approximately 50 countries for the textile, pulp & paper and
animal feed industries. Cautionary Statement for Forward-Looking
Statements Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements
involve risks and uncertainties that could cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. For a discussion of
these risks and uncertainties, please see our filings from time to
time with the Securities and Exchange Commission, which are
available free of charge on the SEC's web site at
http://www.sec.gov, including our Annual Report on Form 10-KSB for
the year ended December 31, 2005, and our subsequent filings with
the SEC. Except as required by law, we expressly disclaim any
intent or obligation to update any forward-looking statements.
Dyadic (AMEX:DIL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Dyadic (AMEX:DIL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024